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ABSTRACT
Eight G protein-coupled receptors comprise the P2Y receptor
family of cell signaling proteins. The goal of the current study
was to define native cell signaling pathways regulated by the
uridine nucleotide sugar-activated P2Y14 receptor (P2Y14-R).
The P2Y14-R was stably expressed in human embryonic kidney
(HEK) 293 and C6 rat glioma cells by retroviral infection. Nu-
cleotide sugar-dependent P2Y14-R activation was examined by
measuring inhibition of forskolin-stimulated cAMP accumula-
tion. The effect of P2Y14-R activation on mitogen-activated
protein kinase signaling also was studied in P2Y14-HEK293
cells and in differentiated HL-60 human myeloid leukemia cells.
UDP-Glc, UDP-galactose, UDP-glucuronic acid, and UDP-N-
acetylglucosamine promoted inhibition of forskolin-stimulated
cAMP accumulation in P2Y14-HEK293 and P2Y14-C6 cells, and
this signaling effect was abolished by pretreatment of cells with
pertussis toxin. Inhibition of cAMP formation by nucleotide
sugars also was observed in direct assays of adenylyl cyclase
activity in membranes prepared from P2Y14-C6 cells. UDP-Glc
promoted concentration-dependent and pertussis toxin-sensi-
tive extracellular signal-regulated kinase (ERK) 1/2 phosphory-
lation in P2Y14-HEK293 cells. P2Y14-R mRNA was not ob-
served in wild-type HL-60 cells but was readily detected in
dimethyl sulfoxide-differentiated cells. Consistent with this ob-
servation, no effect of UDP-Glc was observed in wild-type
HL-60 cells, but UDP-Glc-promoted pertussis toxin-sensitive
activation of ERK1/2 occurred after differentiation. These re-
sults illustrate that the human P2Y14-R signals through Gi to
inhibit adenylyl cyclase, and P2Y14-R activation also leads to
ERK1/2 activation. This work also identifies two stable P2Y14-
R-expressing cell lines and differentiated HL-60 cells as
model systems for the study of P2Y14-R-dependent signal
transduction.
The P2Y14-R is a seven-transmembrane-spanning G pro-
tein-coupled receptor that is activated by UDP-Glc and other
UDP sugars (Chambers et al., 2000). P2Y14-R mRNA is ex-
pressed in stomach, intestine, placental and adipose tissues,
lung, heart, and throughout the brain, and in many types of
immune cells (Lee et al., 2003; Moore et al., 2003; Skelton et
al., 2003; Scrivens and Dickenson, 2006). Consistent with its
prominent immune cell expression, the P2Y14-R has been
implicated in several immune cell functions. Moore et al.
(2003) reported that P2Y14-R mRNA is up-regulated in sev-
eral brain regions after immunological challenge of mice with
lipopolysaccharide. In addition, UDP-Glc was reported to
promote chemotaxis of bone marrow-derived hematopoietic
stem cells (Lee et al., 2003).
The P2Y14-R is a member of a subgroup of P2Y receptors,
which includes the P2Y12 and P2Y13 receptors thought pri-
marily to activate heterotrimeric G proteins of the Gi family,
but a comprehensive understanding of the signal transduc-
tion pathways activated by the P2Y14-R is not available.
Nonetheless, several reports are consistent with the idea that
the P2Y14-R couples to Gi. For example, Chambers and his
colleagues illustrated in their initial study of the cloned hu-
man P2Y14-R that UDP-Glc promotes pertussis toxin-sensi-
tive binding of radiolabeled GTPS to membranes prepared
from HEK293 cells expressing this receptor. Modest UDP-
Glc-promoted inhibition of cAMP accumulation also has been
reported for murine T-lymphocytes (Scrivens and Dickenson,
2005), human neutrophils (Scrivens and Dickenson, 2006),
and C6 glioma cells (Krzemiñski et al., 2008), although the
effects were not shown unambiguously to involve the
P2Y14-R. Other pharmacological studies of the P2Y14-R have
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relied on coexpression with the promiscuous G protein, G16
(Chambers et al., 2000), or with a chimeric Gq (Moore et al.,
2003; Fricks et al., 2008) engineered to couple Gi-activating
receptors to activation of phosphoinositide hydrolysis and
Ca2 mobilization (Coward et al., 1999).
Studies of the P2Y14-R have been limited by inability to
detect and quantify receptor expression directly through the
use of antibodies or radioligand binding assays and also by
the absence of high-affinity, nonhydrolyzable, selective ago-
nists, and competitive antagonists to verify receptor-specific
signal transduction. It is critical that we understand the cell
signaling processes engaged in response to P2Y14-R activa-
tion, and with this goal in mind, we generated two different
cell lines that stably express the human P2Y14-R. Robust
P2Y14-R-dependent inhibition of adenylyl cyclase was ob-
served in both cell lines, and P2Y14-R-dependent MAP kinase
signaling was studied in P2Y14-HEK293 cells. We also dis-
covered that expression of native P2Y14-R is induced during
differentiation of HL-60 human myeloid leukemia cells and
that UDP-Glc promotes activation of MAP kinase signaling
in these cells. The model cell systems reported here should
provide useful platforms for investigation of the P2Y14-R at
the cellular and biochemical level.
Materials and Methods
Cell Culture. HEK293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37°C in a 10% CO2 environment. C6 rat glioma cells were
cultured in DMEM supplemented with 5% FBS in a 5% CO2 envi-
ronment. HL-60 cells were maintained in Iscove’s medium supple-
mented with 10% FBS. Differentiation of HL-60 cells was achieved
by inclusion of 1.3% DMSO in the culture medium for 5 days (Ser-
vant et al., 2000).
P2Y14-R Expression. Human P2Y14-R cDNA was amplified and
ligated into the retroviral expression vector pLXSN as described
previously (Wolff et al., 2005). Retrovirus encoding the P2Y14-R was
produced in PA317 cells according to the method of Johnson et al.
(1998) and was used to infect HEK293 cells or C6 glioma cells.
Geneticin-resistant cells were selected for 2 weeks in medium con-
taining 0.4 mg/ml G418. Clonal HEK293 cells stably expressing the
hP2Y14-R were obtained by performing serial dilutions of cells in
96-well plates and growing clonal populations from a single cell
under selection medium.
Membrane Preparation. Membranes were prepared as de-
scribed previously (Smith and Harden, 1985). In brief, P2Y14-C6 rat
glioma cells were grown on 150-mm dishes until confluent. Cells
were washed gently with phosphate-buffered saline and then lysed
with ice-cold 1 mM Tris, pH 7.4. Cells were harvested by scraping
dishes and homogenized with a glass homogenizer for 10 strokes.
Lysates were centrifuged at 40,000g for 10 min. Membranes were
resuspended in 10 mM Tris, pH 7.4, containing 1 mM EDTA and
centrifuged again at 40,000g for 10 min. Washed membranes were
resuspended in assay buffer (25 mM HEPES, pH 7.4, 5 mM MgCl,
150 mM NaCl, 1 mM EDTA) and used immediately.
cAMP Accumulation. Cells were grown in 24-well plates and
incubated with 1 Ci [3H]adenine/well in serum-free DMEM for 2 h
before assay. Assays were initiated by the addition of HEPES-buff-
ered, serum-free DMEM containing 200 M 3-isobutyl-1-methylxan-
thine (IBMX), with or without drugs, and incubation continued for 12
min at 37°C. Incubations were terminated by aspiration of medium
and addition of 450 l of ice-cold 5% trichloroacetic acid. [3H]cAMP
was isolated by sequential Dowex and alumina chromatography
(Salomon et al., 1974) and quantified by liquid scintillation counting.
Adenylyl Cyclase Activity. Quantification of adenylyl cyclase
activity was carried out according to the procedure described previ-
ously (Harden et al., 1982). In brief, assay tubes on ice contained
drug or buffer and a reaction mix of assay buffer containing, at final
assay concentrations, 0.01 mM [-32P]ATP (10–15 cpm/pmol), 0.5
mM [3H]cAMP (10,000 cpm/assay), 8 mM creatine phosphate, crea-
tine phosphokinase (6 U/assay), 0.01 mM GTP, 0.2 mM IBMX, 25
mM HEPES, pH 7.5, 5 mM MgSO4, 2 mM EDTA, and 150 mM NaCl.
Assays were initiated by the addition of 100 g of membrane protein,
and the incubations were carried out for 12 min at 30°C. The reaction
was terminated with addition of 0.85 ml of ice-cold 5% trichloroacetic
acid. [32P]cAMP was isolated by sequential Dowex and alumina
chromatography and quantified by liquid scintillation counting. Re-
covery of [3H]cAMP over columns averaged 50 to 60%.
MAP Kinase Activation Assays. HEK293 cells were grown on
12-well plates until 70 to 90% confluent. Cells were serum-starved
24 h before assay. Drugs were added to cells for the indicated times,
and the assay was terminated by aspiration of medium. The cells
were washed once with phosphate-buffered saline, and Laemmli
buffer containing 60 M dithiothreitol was added to each well. The
resultant cell lysates were passed through a 27-gauge needle 10
times, heated to 95°C for 5 min, and proteins were resolved by
electrophoresis on a 12.5% polyacrylamide gel. Proteins were trans-
ferred to a nitrocellulose membrane, blocked with 5% bovine serum
albumin, washed with Tris-buffered saline/Tween 20 (20 mM Tris,
pH 7.4, 120 mM NaCl, 0.1% Tween 20), and then incubated with
antibody for phospho-ERK1/2, phospho-p38, or phospho-c-Jun NH2-
terminal kinase (JNK), according to the manufacturer’s directions.
After washing with Tris-buffered saline/Tween 20, membranes were
incubated with horseradish peroxidase-conjugated goat-anti-mouse
(phospho-ERK1/2, phospho-JNK) or goat-anti-rabbit (phospho-p38)
antibody, membranes were washed, incubated with chemilumines-
cent substrate (Pico West system; Thermo Fisher Scientific,
Waltham, MA), and then exposed to film. Membranes were stripped
with 200 mM glycine, pH 2.6, for 1 h at 25°C, then reprobed with a
primary antibody against total MAP kinase to verify equal loading of
lanes. HL-60 cells were serum-starved 24 h before the assay and
resuspended in Hanks’ balanced salt solution for the assay at a
density of 5  106 cells/ml, 0.2 ml/assay. Drugs were added for the
indicated times, and the cells were lysed by adding 1 volume of
Laemmli buffer containing 60 M dithiothreitol to the cells. Lysates
were analyzed as described above.
Reverse Transcriptase-PCR. HL-60 cells were harvested,
washed, and lysed in TRIzol reagent (Invitrogen, Carlsbad, CA).
Total RNA was isolated by chloroform extraction, and isolation of
mRNA was performed using the Oligotex mRNA Mini kit (QIAGEN,
Valencia, CA). cDNA was generated using the reverse transcriptase
(RT) III SuperMix First-Strand Synthesis kit (Invitrogen). P2Y14-R-
specific primers (5-ACTACGCGTCCATCAATTCAA-3 and 5-GT-
TAGTGACATCCTTAACACTCTGGTTGGTGAGAAT-3) were used
in the PCR reactions, and conditions were as follows: 95°C, 30 s;
55°C, 30 s; and 72°C, 1 min, for 38 cycles. PCR products were
analyzed by 2% agarose gel electrophoresis and visualized by
ethidium bromide staining. Negative controls for each sample were
performed without reverse transcriptase added to the reaction.
Data Analysis. EC50 values were determined using Prism soft-
ware (GraphPad Software Inc., San Diego, CA) and are presented as
mean  S.E. Statistical significance was determined by analysis of
variance, and p  0.02 was considered statistically significant. All
experiments were repeated at least three times.
Materials. IBMX, creatine phosphate, creatine phosphokinase,
forskolin, formyl-Met-Leu-Phe (fMLP), and GTP were purchased
from Sigma-Aldrich (St. Louis, MO). UDP-Glc, UDP-galactose, UDP-
glucuronic acid, and UDP-N-acetylglucosamine were all from Fluka
(Buchs, Switzerland), purchased through Sigma-Aldrich. HPLC
analysis of the UDP-Glc used in the current experiments revealed
	98% purity. ATP was purchased from GE Healthcare (Chalfont St.
Giles, UK). Pertussis toxin was purchased from List Biological Lab-
oratories Inc.(Campbell, CA). [3H]Adenine and [3H]cAMP were pur-
chased from American Radiolabeled Chemicals (St. Louis, MO).
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[-32P]ATP was purchased from PerkinElmer Life and Analytical
Sciences (Waltham, MA). Antibodies for P-ERK1/2, ERK1/2, P-p38,
p38, P-JNK, and JNK were purchased from Cell Signaling Technol-
ogy Inc. (Danvers, MA). All cell culture medium and serum were
from Invitrogen. The protease-activated receptor (PAR) agonist pep-
tide SLIGKV was a generous gift from Dr. Joann Trejo. Anisomycin
and sorbitol were kind gifts from Dr. Gary Johnson.
Results
UDP Sugars Promote Inhibition of Forskolin-Stimu-
lated cAMP Formation in Cells Stably Expressing the
Human P2Y14-R. To examine potential regulation of adeny-
lyl cyclase activity downstream of the human P2Y14-R, we
stably expressed this receptor in HEK293 cells. UDP-Glc
promoted concentration-dependent inhibition of forskolin-
stimulated accumulation of cAMP in P2Y14-R-expressing
HEK293 cells. An EC50 value of 82  11 nM (n 
 3) was
observed for UDP-Glc, and the maximal inhibition of forsko-
lin-stimulated cAMP accumulation ranged from 50 to 60%
(Fig. 1). In contrast, no effect of UDP-Glc was observed on
basal or forskolin-stimulated cAMP accumulation in
HEK293 cells infected with vector alone. Preincubation of
P2Y14-HEK293 cells with pertussis toxin resulted in com-
plete loss of UDP-Glc-dependent inhibition of cAMP accumu-
lation (Fig. 1), indicating that the P2Y14-R signals through
G-subunits of the Gi family.
Although UDP-Glc is reported to be a full agonist at the
P2Y14-R, several studies of the P2Y14-R have reported vari-
able effects of other nucleotide sugars (Chambers et al., 2000;
Scrivens and Dickenson, 2006). Therefore, we tested the ca-
pacity of UDP sugars to activate the P2Y14-R in P2Y14-
HEK293 cells. UDP-galactose, UDP-glucuronic acid, and
UDP-N-acetylglucosamine all promoted inhibition of cAMP
accumulation, and the maximal inhibition observed was sim-
ilar to that of UDP-Glc. The potencies of UDP-galactose and
UDP-glucuronic acid were similar to that of UDP-Glc,
whereas UDP-N-acetylglucosamine exhibited an approxi-
mately 10-fold higher EC50 value (Fig. 2; Table 1). Although
marked P2Y14 receptor-dependent effects on cAMP accumu-
lation were observed in P2Y14-HEK293 cells, incubation of
these cells with UDP-Glc had no effect on inositol phosphate
accumulation (data not shown).
We concluded that it was important to stably express the
P2Y14-R in several cell backgrounds. Previous studies by our
lab and other labs revealed robust inhibition of adenylyl
cyclase in C6 rat glioma cells expressing several different G
protein-coupled receptors (Schachter et al., 1997; Thomas et
al., 2000; Castillo et al., 2007). Therefore, we also infected C6
cells with the recombinant pLXSN virus harboring the
hP2Y14-R coding sequence. Again, although UDP-Glc had no
effect on cAMP accumulation in C6 cells expressing empty
vector alone, robust inhibitory effects were observed with
UDP-Glc in P2Y14-R-expressing C6 cells, with 70 to 80%
maximal inhibition of forskolin-stimulated accumulation of
cAMP (Fig. 3). An EC50 value of 107  68 nM was determined
(Table 1). The action of UDP-Glc in P2Y14-C6 cells was com-
pletely blocked by pretreatment of the cells with pertussis
toxin (Fig. 3). The concentration-dependent inhibition of
cAMP formation with other UDP sugars also was estab-
lished, and the EC50 values are reported in Table 1.
Effect of UDP-Glc on Adenylyl Cyclase Activity in
Membranes from P2Y14-R-Expressing C6 Cells. Based
on the robust P2Y14-R-dependent inhibition of cAMP accu-
mulation observed in C6 glioma cells, we also isolated plasma
membrane-enriched fractions to determine whether UDP-
Glc- and P2Y14-R-dependent inhibition of adenylyl cyclase
activity could be observed in a cell-free system. Although no
effect of UDP-Glc was observed in membranes from control
cells, approximately 50% inhibition of forskolin-stimulated
Fig. 1. Concentration-dependent and pertus-
sis toxin-sensitive inhibition of cAMP accumu-
lation promoted by UDP-Glc in P2Y14-HEK293
cells. Empty vector-infected (left) or P2Y14-R-
expressing (middle) cells were labeled with
[3H]adenine 18 h before assay. Cells were in-
cubated with 200 M IBMX in the absence ()
or presence of 30 M forskolin and the indi-
cated concentrations of UDP-Glc (f) for 12 min
before quantification of [3H]cAMP accumula-
tion. P2Y14-R-expressing (right) cells were pre-
incubated overnight with 100 ng/ml pertussis
toxin, and [3H]cAMP accumulation was mea-
sured in the presence of 200 M IBMX alone
(open bars), 200 M IBMX  30 M forskolin
(filled bars), or 200 M IBMX  30 M forsko-
lin  10 M UDP-Glc (hatched bars). The data
shown are presented as mean  S.E. and are
representative of results from three indepen-
dent experiments.
Fig. 2. UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglu-
cosamine inhibit accumulation of cAMP in P2Y14-HEK293 cells. [
3H]Ade-
nine-labeled P2Y14-HEK293 cells were incubated with 200 M IBMX
alone () or IBMX with 30 M forskolin and varying concentrations of
UDP-Glc (f), UDP-galactose (), UDP-glucuronic acid (Œ), or UDP-N-
acetylglucosamine (). Data shown are mean  S.E. and are represen-
tative of results of three independent experiments.
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adenylyl cyclase activity was observed in the presence of 10
M UDP-Glc in membranes isolated from P2Y14-C6 glioma
cells (Fig. 4). This UDP-Glc-promoted response did not occur
in membranes from P2Y14-C6 cells pretreated with pertussis
toxin.
MAP Kinase Activation by UDP-Glc in P2Y14-
HEK293 Cells. Many important biological processes are reg-
ulated by MAP kinase signaling pathways. To assess the
capacity of the P2Y14-R to activate MAP kinase signaling
cascades, P2Y14-HEK293 cells were treated with UDP-Glc,
and cell lysates were analyzed for phosphorylated ERK1/2 by
Western blotting. Although no effect was observed in mock-
infected cells, UDP-Glc-dependent ERK1/2 phosphorylation
occurred in P2Y14-HEK293 cells (Fig. 5A).
The time course for UDP-Glc activation of ERK1/2 was
compared with that occurring as a consequence of activation
of PAR2, which is natively expressed in HEK293 cells
(Amadesi et al., 2004; Dai et al., 2007). Incubation of cells
with the PAR2 agonist peptide SLIGKV (100 M) resulted in
marked phosphorylation of ERK1/2 within 5 min, but phos-
phorylation quickly diminished thereafter. In contrast, UDP-
Glc-dependent activation of ERK1/2 was not maximal until
at least 15 min of incubation and was retained for at least 30
min. The effect of UDP-Glc on ERK1/2 phosphorylation was
concentration-dependent (Fig. 5C), and the EC50 (30 nM)
observed was similar to that obtained in studies of inhibition
of cAMP accumulation in these cells. As was observed in the
studies of adenylyl cyclase activity, P2Y14-R-regulated
ERK1/2 phosphorylation was not observed in cells preincu-
bated with pertussis toxin (Fig. 5B).
The capacity of the P2Y14-R to activate p38 and JNK also
was examined. Although p38 was phosphorylated with a
peak response observed within 5 min after treatment of cells
with sorbitol, no UDP-Glc-dependent activation of p38 was
observed at any time point up to 60 min (Fig. 5D). In contrast
to a robust activation observed in the presence of anisomycin,
we also observed no effect of UDP-Glc on JNK phosphoryla-
tion (Fig. 5D).
Functional P2Y14-R Are Endogenously Expressed in
Differentiated HL-60 Cells. With the goal of identifying a
cell line that natively expresses the P2Y14-R, we tested by
RT-PCR several candidate cell lines previously reported to
express P2Y14-R mRNA and other cell lines derived from
tissues reported to express this receptor (Chambers et al.,
2000; Moore et al., 2003; Skelton et al., 2003). Although no
P2Y14-R mRNA was detected in undifferentiated HL-60 cells,
differentiation of these cells with 1.3% DMSO to a neutro-
Fig. 3. UDP-Glc promotes pertussis toxin-sensitive inhibition of cAMP
accumulation in P2Y14-C6 cells. Empty vector-infected (left) C6 rat gli-
oma cells were prelabeled with [3H]adenine and then incubated in the
presence of 200 M IBMX alone (open bar), 200 M IBMX  30 M
forskolin (filled bar), or 200 M IBMX  30 M forskolin  10 M
UDP-Glc (striped bar). P2Y14-C6 cells (right) were incubated in the ab-
sence or presence of 100 ng/ml pertussis toxin before quantification of
[3H]cAMP accumulation in the presence of 200 M IBMX alone (open
bars), 200 M IBMX  30 M forskolin (filled bars), or 200 M IBMX 
30 M forskolin  10 M UDP-Glc (striped bars). Data shown are
presented as mean  S.E. and are representative of results from three
independent experiments.
Fig. 4. UDP-Glc-dependent inhibition of adenylyl cyclase by UDP-Glc in
membranes from P2Y14-C6 cells. Membranes were isolated from
P2Y14-C6 cells or from cells pretreated with 100 ng/ml pertussis toxin
overnight. Membranes were incubated with 200 M IBMX in the absence
(open bars) or presence (filled bars) of 30 M forskolin or with 200 M
IBMX  30 M forskolin  10 M UDP-Glc (hatched bars) as described
under Materials and Methods. [32P]cAMP was isolated by sequential
Dowex-alumina chromatography. Data shown are the mean  S.E. of
three independent experiments, plotted as a percentage of maximal for-
skolin-stimulated enzyme activity.
TABLE 1
EC50 values for P2Y14-R agonists in P2Y14-HEK293 and P2Y14-C6 cells
3HAdenine-labeled cells were incubated with IBMX (200 M), forskolin (30 M), and varying concentrations of UDP-glucose, UDP-galactose, UDP-glucuronic acid, or
UDP-N-acetylglucosamine for 15 min. 3HcAMP was quantified as described under Materials and Methods. EC50 values and percentage inhibition were determined with




EC50  S.E. Maximal Inhibition EC50  S.E. Maximal Inhibition
nM % nM %
UDP-glucose 82  11 51  1 92  51 76  0.5
UDP-galactose 96  29 60  2 240  53 72  8
UDP-glucuronic acid 60  7 55  0.3 108  66 79  1
UDP-N-acetylglucosamine 919  205 58  3 225  68 74  8
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phil-like cell resulted in a marked increase in expression of
P2Y14-R mRNA (Fig. 6A).
We also investigated the cell signaling responses discussed
above to determine whether functional P2Y14-R could be
observed in differentiated HL-60 cells. In multiple experi-
ments, 100 M UDP-Glc exhibited no effect on cAMP accu-
mulation promoted by forskolin, amthamine, an agonist for
the Gs-coupled H2 histamine receptor, or forskolin 
amthamine (data not shown). Although a formyl peptide
receptor (FPR) is natively expressed by HL-60 cells (Boulay
et al., 1990; Klinker et al., 1996), we also failed to observe
effects of 1 M fMLP on cAMP accumulation in these cells.
Potential activation of the MAP kinase signaling pathway
also was studied in HL-60 cells. Although no effect of UDP-
Glc was observed in wild-type cells, time-dependent activa-
tion of ERK1/2 by UDP-Glc was observed after differentia-
tion of the cells. This effect was apparent within 5 min and
peaked within 30 min (Fig. 6B). In contrast to the time course
of the phosphorylation response to UDP-Glc, cells treated
with 1 M fMLP exhibited a robust ERK1/2 activation at 5
min that quickly diminished thereafter (Fig. 6C). Neither
Fig. 5. UDP-Glc-promoted activation of MAP kinase signaling in P2Y14-
HEK293 cells. A, empty vector or P2Y14-R-expressing HEK293 cells were
serum-starved for 18 h and then incubated with 100 M UDP-Glc or 100
M SLIGKV for the times indicated. Cell lysates were subjected to
SDS-polyacrylamide gel electrophoresis, the samples were transferred to
nitrocellulose membranes, and the samples were probed with antibodies
for phospho-ERK1/2 and total ERK1/2 as described under Materials and
Methods. Results shown are representative of three individual experi-
ments. B, cells were pretreated in the absence (PTX) or presence
(PTX) of 100 ng/ml pertussis toxin overnight, then treated with UDP-
Glc for 15 min. Results shown are representative of those obtained from
three independent experiments. C, cells were incubated with varying
concentrations of UDP-Glc for 15 min. Phospho-ERK1/2 and ERK1/2
were quantified using Scion Image software (Scion Corporation, Freder-
ick, MD) and graphed using GraphPad Prism software. Each phospho-
ERK1/2 lane was normalized to the corresponding ERK1/2 control and
plotted as fold stimulation over control. Data shown are the average 
S.E. of four independent experiments. D, P2Y14-HEK293 cells were
treated with 0.2 M sorbitol, 0.01 mg/ml anisomycin, or 100 M UDP-Glc
for the indicated times. Phospho-p38, phospho-JNK, total p38, and total
JNK were determined as described under Materials and Methods.
Fig. 6. UDP-Glc-promoted activation of MAP kinase activation in differ-
entiated HL-60 cells. A, RT-PCR of undifferentiated (DMSO) or differ-
entiated (DMSO) HL-60 cells in the absence () or presence () of RT.
PCR with hP2Y14-R-specific primers was performed as described under
Materials and Methods. B, wild-type or differentiated (see Materials and
Methods) HL-60 cells were serum-starved for 18 h before addition of 100
M UDP-Glc, and incubation was continued for the indicated times.
Western blots for phospho-ERK1/2 and ERK1/2 were generated as de-
scribed under Materials and Methods. Phospho-ERK1/2 was quantified
using Scion Image software and graphed using GraphPad Prism soft-
ware. Each phospho-ERK1/2 lane was normalized to the corresponding
ERK1/2 control and plotted as -fold stimulation over control. Data shown
are the mean  S.E. of six independent experiments (, p  0.02). C,
serum-starved, differentiated HL-60 cells were incubated with 1 M
formyl-Met-Leu-Phe for the indicated times, and lysates were analyzed as
described under Materials and Methods. D, differentiated HL-60 cells
were treated in the absence (PTX) or presence (PTX) of 200 ng/ml
pertussis toxin for 4 h before assay. Cells were incubated for the indicated
times with 100 M UDP-Glc and phospho-ERK1/2, and total ERK1/2 was
quantified as described under Materials and Methods.
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UDP-Glc- nor fMLP-dependent ERK1/2 activation was ob-
served in cells preincubated with pertussis toxin (Fig. 6D),
consistent with the notion that the UDP-Glc-promoted
ERK1/2 activation in differentiated HL-60 cells occurs
through a mechanism involving Gi in differentiated HL-60
cells.
Discussion
In this report, we demonstrate that the human P2Y14-R
couples to inhibition of adenylyl cyclase in a pertussis toxin-
sensitive manner in HEK293 and C6 cells stably expressing
this receptor. This work provides the first unequivocal dem-
onstration of P2Y14-R-dependent inhibition of adenylyl cy-
clase in a membrane preparation. Robust stimulation of MAP
kinase signaling also occurs with activation of the P2Y14-R.
This was the predominant activity observed with native
P2Y14-R in differentiated HL-60 human myeloid leukemia
cells.
UDP-Glc is released from many cell types. This phenome-
non was initially demonstrated by Lazarowski et al. (2003),
who illustrated both basal and mechanically induced release
of UDP-Glc from multiple mammalian cell types. Constitu-
tive release of UDP-Glc also occurs in yeast (Esther et al.,
2008). Although the mechanism(s) underlying UDP-Glc re-
lease is not well established, calcium-dependent release of
UDP-Glc was demonstrated in Calu-3 cells (Kreda et al.,
2007), and UDP-Glc release occurred downstream of throm-
bin receptor-promoted signaling pathways in human astro-
cytoma 1321N1 cells (Kreda et al., 2008).
UDP sugars in addition to UDP-Glc are predictably
present in the extracellular space. UDP-Glc, UDP-galactose,
UDP-glucuronic acid, and UDP-N-acetylglucosamine all
were reported previously as potent agonists of the P2Y14-R in
test systems that involved coexpression of the receptor with
a phospholipase C-activating G protein (Chambers et al.,
2000; Freeman et al., 2001). Our results measuring re-
sponses of a native signaling pathway also indicate that
these four UDP sugars are full agonists and exhibit relatively
similar potencies. It remains to be elucidated which one or
more of these molecules is the endogenous agonist(s) for the
receptor. Indeed, multiple UDP sugars likely are physiolog-
ical agonists for the P2Y14-R, such that the activating ligand
may differ according to tissue or cell type.
Our findings that neither UDP-Glc nor fMLP had an effect
on cAMP accumulation in differentiated HL-60 cells indi-
cates that activated Gi does not couple to inhibition of adeny-
lyl cyclase in these cells. Perhaps the isoforms of adenylyl
cyclase expressed in these cells are not subject to inhibition
by Gi, as has been demonstrated for neutrophils (Mahadeo et
al., 2007). HL-60 cells gain a neutrophil phenotype upon
differentiation and, therefore, are likely to reflect receptor-
promoted signaling responses that are characteristic of neu-
trophils. Receptor-promoted inhibition of adenylyl cyclase
has not been unequivocally demonstrated in neutrophils, and
we are unaware of studies clearly defining the signaling
pathways downstream of Gi-coupled receptors in these cells.
A small inhibition of cAMP accumulation was reported to
occur upon incubation of neutrophils with UDP-Glc (Scrivens
and Dickenson, 2006). However, it is unclear whether this
was a P2Y14-R-mediated effect.
Gi-coupled GPCR activate MAP kinase signaling, and we
illustrate here that UDP-Glc-dependent activation of ERK1/2
occurs in P2Y14-HEK293 cells. Although P2Y14-R were not
detected in undifferentiated HL-60 cells, a message for the
P2Y14-R was observed upon differentiation of HL-60 cells,
and occurrence of UDP-Glc-promoted MAP kinase signaling
indicated the presence of functional P2Y14-R. RT-PCR anal-
yses previously demonstrated that neutrophils express
P2Y14-R at the RNA level (Chen et al., 2006). However,
P2Y14-R were not detected in HL-60 cells, and it is unclear
whether differentiated HL-60 cells were examined by these
authors.
HL-60 cells have been used as a model of neutrophil-like
cells that undergo differentiation-associated morphological
and functional changes including up-regulation of chemoat-
tractant receptors and the capacity to chemotax (Hauert et
al., 2002). Differentiated HL-60 cells exhibit capacities to
generate superoxide, ingest particles, and degranulate with
efficiencies similar to that of neutrophils (Newburger et al.,
1979). In addition, they have distinct technical advantages
over primary cells, such as viability and transfectability.
Differentiated HL-60 cells also have been used as a model
system for studies of FPR, and consistent with previous ob-
servations (Rane et al., 1997; Christophe et al., 2002; Paruch
et al., 2006), we observed fMLP-promoted ERK1/2 activation
in differentiated HL-60 cells. These findings establish differ-
entiated HL-60 cells as a model system for investigation of
biological functions of the P2Y14-R.
The duration of P2Y14-R-promoted ERK1/2 phosphoryla-
tion in HEK293 cells and HL-60 cells was prolonged com-
pared with that of other G protein-coupled receptors. PAR2,
which promoted very transient ERK1/2 activation in
HEK293 cells, is known to couple to Gi, G12/13, and Gq (Fyfe
et al., 2005). The fMLP receptor, FPR, has been reported to
couple to Gi, but the mechanism linking FPR to ERK1/2
phosphorylation is not clear (Selvatici et al., 2006; Huet et
al., 2007; Kam et al., 2007). Therefore, it is possible that the
signaling pathway(s) responsible for P2Y14-R-promoted MAP
kinase signaling differs from that engaged by PAR2 or FPR.
We speculate that pertussis toxin-sensitive G-subunits are
necessary but not sufficient, and additional pathways or reg-
ulatory mechanisms are involved in the MAP kinase re-
sponse downstream of one or more of these receptors. Our
studies do not rule out the possibility that the P2Y14-R de-
sensitizes at a slower rate than PAR2 in HEK293 cells or
FPR in HL-60 cells. Additional studies will be necessary to
address questions about the mechanism of P2Y14-R-depen-
dent activation of MAP kinase, but its pertussis toxin sensi-
tivity clearly indicates that Gi is an important signaling
component in the pathway.
In summary, this work unequivocally demonstrates that
the human P2Y14-R promotes inhibition of adenylyl cyclase
and activation of MAP kinase signaling pathways. Our work
also provides several model cell lines for study of P2Y14-R
signaling and its potential role in neutrophil biology.
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Krzemiñski P, Pomorski P, and Barañska J (2008) The P2Y14 receptor activity in
glioma C6 cells. Eur J Pharmacol 594:49–54.
Lazarowski ER, Shea DA, Boucher RC, and Harden TK (2003) Release of cellular
UDP-glucose as a potential extracellular signaling molecule. Mol Pharmacol 63:
1190–1197.
Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I,
Dombkowski D, Olson DP, et al. (2003) P2Y-like receptor, GPR105 (P2Y14), iden-
tifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes
Dev 17:1592–1604.
Mahadeo DC, Janka-Junttila M, Smoot RL, Roselova P, and Parent CA (2007) A
chemoattractant-mediated Gi-coupled pathway activates adenylyl cyclase in hu-
man neutrophils. Mol Biol Cell 18:512–522.
Moore DJ, Murdock PR, Watson JM, Faull RL, Waldvogel HJ, Szekeres PG, Wilson
S, Freeman KB, and Emson PC (2003) GPR105, a novel Gi/o-coupled UDP-glucose
receptor expressed on brain glia and peripheral immune cells, is regulated by
immunologic challenge: possible role in neuroimmune function. Brain Res Mol
Brain Res 118:10–23.
Newburger PE, Chovaniec ME, Greenberger JS, and Cohen HJ (1979) Functional
changes in human leukemic cell line HL-60: a model for myeloid differentiation.
J Cell Biol 82:315–322.
Paruch S, El-Benna J, Djerdjouri B, Marullo S, and Périanin A (2006) A role of
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